Enorama Pharma Ab Stock Shares Owned By Insiders
| ERMA Stock | SEK 3.30 0.05 1.54% |
Enorama Pharma AB fundamentals help investors to digest information that contributes to Enorama Pharma's financial success or failures. It also enables traders to predict the movement of Enorama Stock. The fundamental analysis module provides a way to measure Enorama Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enorama Pharma stock.
Enorama |
Enorama Pharma AB Company Shares Owned By Insiders Analysis
Enorama Pharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Enorama Pharma Shares Owned By Insiders | 78.21 % |
Most of Enorama Pharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enorama Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 78% of Enorama Pharma AB are shares owned by insiders. This is much higher than that of the Healthcare sector and notably higher than that of the Drug Manufacturers - Specialty & Generic industry. The shares owned by insiders for all Sweden stocks is notably lower than that of the firm.
Enorama Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enorama Pharma's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enorama Pharma could also be used in its relative valuation, which is a method of valuing Enorama Pharma by comparing valuation metrics of similar companies.Enorama Pharma is currently under evaluation in shares owned by insiders category among its peers.
Enorama Fundamentals
| Return On Equity | -32.88 | |||
| Return On Asset | -0.53 | |||
| Operating Margin | (3.11) % | |||
| Current Valuation | 42.1 M | |||
| Shares Outstanding | 10.69 M | |||
| Shares Owned By Insiders | 78.21 % | |||
| Shares Owned By Institutions | 1.31 % | |||
| Price To Book | 7.67 X | |||
| Price To Sales | 3.82 X | |||
| Revenue | 11.04 M | |||
| Gross Profit | 3.9 M | |||
| EBITDA | (25.56 M) | |||
| Net Income | (27.74 M) | |||
| Cash And Equivalents | 2.01 M | |||
| Cash Per Share | 0.38 X | |||
| Total Debt | 1.7 M | |||
| Debt To Equity | 6.00 % | |||
| Current Ratio | 0.52 X | |||
| Book Value Per Share | (1.22) X | |||
| Cash Flow From Operations | (30.16 M) | |||
| Earnings Per Share | (4.92) X | |||
| Number Of Employees | 10 | |||
| Beta | 1.65 | |||
| Market Capitalization | 89.44 M | |||
| Total Asset | 50.93 M | |||
| Z Score | 31.2 | |||
| Net Asset | 50.93 M |
About Enorama Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enorama Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enorama Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enorama Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.